Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1Head and Neck Squamous Cell Cancer 1Glioblastoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 26Nivolumab 10Cisplatin 9Gemcitabine 8Docetaxel 6enfortumab vedotin 5atezolizumab 5Ipilimumab 5Carboplatin 5sacituzumab govitecan 4Paclitaxel 4Pemetrexed 3Cyclophosphamide 3vofatamab 2tremelimumab 2tislelizumab 2regorafenib 2lenvatinib 2epacadostat 2durvalumab 2avelumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2Bevacizumab 2B701 protein, Human herpesvirus 6 2ALT-803 2yeast-CEA vaccine 1toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Transitional Cell × rocakinogene sifuplasmid × Clear all
NCT03502785 2025-07-10

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Inovio Pharmaceuticals

Phase 1/2 Completed
35 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡